| 1 | The 2016 revision of the World Health Organization classification of lymphoid neoplasms | Blood | 2016 | 5,442 |
| 2 | CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma | New England Journal of Medicine | 2002 | 4,068 |
| 3 | A clinical approach to diagnosis of autoimmune encephalitis | Lancet Neurology, The | 2016 | 3,133 |
| 4 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia | 2022 | 2,970 |
| 5 | Prone Positioning in Severe Acute Respiratory Distress Syndrome | New England Journal of Medicine | 2013 | 2,618 |
| 6 | DNA methylation-based classification of central nervous system tumours | Nature | 2018 | 2,233 |
| 7 | EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent | European Urology | 2017 | 2,204 |
| 8 | EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent | European Urology | 2021 | 2,199 |
| 9 | Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy | Nature Reviews Immunology | 2013 | 1,966 |
| 10 | Strategies and challenges for the next generation of antibody–drug conjugates | Nature Reviews Drug Discovery | 2017 | 1,838 |
| 11 | Autoantibodies against type I IFNs in patients with life-threatening COVID-19 | Science | 2020 | 1,822 |
| 12 | Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis | Lancet, The | 2022 | 1,489 |
| 13 | Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) | Clinical Neurophysiology | 2014 | 1,469 |
| 14 | Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS) | Clinical Neurophysiology | 2017 | 1,339 |
| 15 | Hepatitis B virus infection | Lancet, The | 2014 | 1,169 |
| 16 | Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial | Lancet, The | 2004 | 1,152 |
| 17 | Multiple sclerosis | Nature Reviews Disease Primers | 2018 | 1,144 |
| 18 | Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte | Blood | 2010 | 1,138 |
| 19 | EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer | European Urology | 2017 | 1,100 |
| 20 | Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Lancet Oncology, The | 2015 | 1,087 |
| 21 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Annals of Oncology | 2019 | 1,072 |
| 22 | Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study | CardioVascular and Interventional Radiology | 2009 | 1,060 |
| 23 | Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach | Lancet Infectious Diseases, The | 2013 | 1,051 |
| 24 | Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report | American Journal of Respiratory and Critical Care Medicine | 2016 | 1,046 |
| 25 | Modern diagnosis of GERD: the Lyon Consensus | Gut | 2018 | 1,013 |
| 26 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma | JAMA - Journal of the American Medical Association | 2015 | 950 |
| 27 | Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial | Lancet, The | 2012 | 938 |
| 28 | Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias | PLoS ONE | 2008 | 937 |
| 29 | Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial | Lancet, The | 2012 | 914 |
| 30 | Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury | Critical Care | 2013 | 906 |
| 31 | The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women | Osteoporosis International | 2007 | 894 |
| 32 | Niemann-Pick disease type C | Orphanet Journal of Rare Diseases | 2010 | 875 |
| 33 | New driver mutations in non-small-cell lung cancer | Lancet Oncology, The | 2011 | 870 |
| 34 | Event-related potentials in clinical research: Guidelines for eliciting, recording, and quantifying mismatch negativity, P300, and N400 | Clinical Neurophysiology | 2009 | 863 |
| 35 | Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study | Lancet Oncology, The | 2019 | 855 |
| 36 | Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study | Lancet Neurology, The | 2013 | 815 |
| 37 | EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer | European Urology | 2021 | 811 |
| 38 | Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study | Lancet Oncology, The | 2019 | 808 |
| 39 | Esophageal motility disorders on high‐resolution manometry: Chicago classification version 4.0© | Neurogastroenterology and Motility | 2021 | 787 |
| 40 | Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic | Circulation | 2020 | 785 |
| 41 | Evolving Therapies for Myocardial Ischemia/Reperfusion Injury | Journal of the American College of Cardiology | 2015 | 778 |
| 42 | Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) | Lancet, The | 2016 | 760 |
| 43 | Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society | European Heart Journal | 2021 | 753 |
| 44 | Advances in the understanding and treatment of sepsis-induced immunosuppression | Nature Reviews Nephrology | 2017 | 751 |
| 45 | Assessment of Myocardial Fibrosis With Cardiovascular Magnetic Resonance | Journal of the American College of Cardiology | 2011 | 749 |
| 46 | Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study | Lancet, The | 2012 | 746 |
| 47 | Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial | Lancet, The | 2011 | 718 |
| 48 | Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management | European Respiratory Journal | 2016 | 712 |
| 49 | Epilepsy: new advances | Lancet, The | 2015 | 695 |
| 50 | CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner | Journal of Experimental Medicine | 2005 | 684 |
